Clare Scott

Abstract 1074: Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma

Cassandra J Vandenberg, Gwo-Yaw Ho, Ksenija Nesic, Elizabeth M Swisher, Sean M Grimmond, Matthew J Wakefield, Holly E Barker, David D Bowtell, Clare L Scott

Conference Proceedings  |  2021  |  Experimental and Molecular Therapeutics

Abstract 2057: BRCA1 D11q isoform expression impacts PARP inhibitor responses in high grade serous ovarian carcinoma patient derived xenografts

Ksenija Nesic, Cassandra J Vandenberg, Olga Kondrashova, John J Krais, Neil Johnson, Elizabeth M Swisher, Matthew J Wakefield, Clare L Scott

Conference Proceedings  |  2021  |  Molecular and Cellular Biology/Genetics

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.

Zhen Xu, Cassandra J Vandenberg, Elizabeth Lieschke, Ladina Di Rago, Clare L Scott, Ian J Majewski

Journal article  |  2021  |  Mol Cancer Res

Patients with cancer treated with PARP inhibitors (PARPi) experience various side effects, with hematologic toxicity being most co..

T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review

Jessica WY Wu, Sudiksha Dand, Lachlan Doig, Anthony T Papenfuss, Clare L Scott, Gwo Ho, Joshua D Ooi

Journal article  |  2021  |  FRONTIERS IN IMMUNOLOGY

Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive a..

WhiMSICAL: A global Waldenstrom's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes

Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter L DeNardis, Javier Haurat, Marita Black, Stephen Opat, Damien Kee, Shirley D'Sa, Marie Jose Kersten, Ruth L Spearing, Maria Lia Palomba, Adam J Olszewski, Carl Harrington, Clare L Scott, Judith Trotman

Journal article  |  2021  |  AMERICAN JOURNAL OF HEMATOLOGY

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis

Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, Jonathan A Ledermann, Robert L Coleman, Mansoor R Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Ralph Bloomfield, Sandra Goble, Ping Wang, Rosalind M Glasspool, Clare L Scott

Journal article  |  2021  |  CANCER

BACKGROUND: The authors performed a meta-analysis to better quantify the benefit of maintenance poly(ADP-ribose) polymerase inhibi..

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors

Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C Chueh, Judy Doherty, Francois Vaillant, Gwo-Yaw Ho, Matthew J Wakefield, Clare E Weeden, Alvin Kamili, Jayne Murray, Sela T Po'uha, Janet Weinstock, Serena R Kane, Maree C Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J Kershaw, et al.

Journal article  |  2021  |  CELL DEATH & DISEASE

Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limita..

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana GZ Lim, Brendan NK Pang, Sherlly Lim, Joe Yeong, Anthony Karnezis, Derek S Chiu, Samuel Leung, David G Huntsman, Anna S Sedukhina, Ko Sato, Monique D Topp, Clare L Scott, Hyungwon Choi, Naina R Patel, et al.

Journal article  |  2021  |  EMBO MOLECULAR MEDICINE

Early relapse after platinum chemotherapy in epithelial ovarian cancer (EOC) portends poor survival. A-priori identification of pl..

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Conference Proceedings  |  2021  |  MODERN PATHOLOGY

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis

Felix KF Kommoss, Dane Cheasley, Matthew J Wakefield, Clare L Scott, Ian G Campbell, C Blake Gilks, Kylie Gorringe

Journal article  |  2020  |  HISTOPATHOLOGY

Recently, genetic analyses of primary mucinous ovarian tumours (MOT) have considerably enhanced our understanding of the biology o..